Macrophages Kill Human Papillomavirus Type 16 E6-E
http://www.100md.com
病菌学杂志 2005年第1期
Departments of Medicine
Integrated Department of Immunology, National Jewish Medical and Research Center and the University of Colorado Health Sciences Center
Cancer Center
Departments of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, Colorado
ABSTRACT
The expression of adenovirus serotype 2 or 5 (Ad2/5) E1A sensitizes cells to killing by NK cells and activated macrophages, a property that correlates with the ability of E1A to bind the transcriptional coadaptor proteins p300-CBP. The E6 oncoproteins derived from the high-risk human papillomaviruses (HPV) interact with p300 and can complement mutant forms of E1A that cannot interact with p300 to induce cellular immortalization. Therefore, we determined if HPV type 16 (HPV16) E6 could sensitize cells to killing by macrophages and NK cells. HPV16 E6 expression sensitized human (H4 and C33A) and murine (MCA-102) cell lines to lysis by macrophages but not by NK cells. The lysis of cells that expressed E6 by macrophages was p53 independent but dependent on the production of tumor necrosis factor alpha (TNF-) or nitric oxide (NO) by macrophages. Unlike cytolysis assays with macrophages, E6 expression did not significantly sensitize cells to lysis by the direct addition of NO or TNF-. Like E1A, E6 has been reported to sensitize cells to lysis by TNF- by inhibiting the TNF--induced activation of NF-B. We found that E1A, but not E6, blocked the TNF--induced activation of NF-B, an activity that correlated with E1A-p300 binding. In summary, Ad5 E1A and HPV16 E6 sensitized cells to lysis by macrophages. Unlike E1A, E6 did not block the ability of TNF- to activate NF-B or sensitize cells to lysis by NK cells, TNF-, or NO. Thus, there appears to be a spectrum of common and unique biological activities that result as a consequence of the interaction of E6 or E1A with p300-CBP.
INTRODUCTION
Adenoviruses (Ad) and human papillomaviruses (HPV) are common human pathogens that are able to transform human cells. High-risk HPV (e.g., HPV type 16 [HPV16], HPV18, and HPV31) are the etiologic agents for greater than 95% of cervical carcinomas, the second most common cancer in females worldwide (4, 53). In contrast to HPV, Ad do not appear to be oncogenic in humans (31). Ad and HPV transform cells by similar molecular mechanisms. E7 and E1A are the primary immortalizing genes of HPV and Ad, respectively. HPV E6 and Ad E1B increase the efficiency of E7- and E1A-induced immortalization and are required for complete transformation of cells. The E1A and E7 oncoproteins express homologous conserved regions, conserved region 1 (CR1) and conserved region 2 (CR2). The conserved regions of E1A and E7, which are interchangeable for immortalization function, interact with and inhibit cellular growth regulatory proteins (pRb, p107, p130, and cyclin A) (5, 20, 34, 50-52, 58, 77). Through different molecular mechanisms, the Ad E1B-55K (66, 80) and HPV E6 (55, 68) oncoproteins inhibit the function of p53. The inability of Ad to be oncogenic in humans is puzzling because the E1A and E1B oncogenes fully transform human cells (30), and cells transformed by these oncogenes form tumors in immunodeficient mice (10).
We hypothesize that one factor that influences the dissimilar oncogenicities of Ad and HPV is differences in the capacities of Ad- or HPV-transformed cells to elicit an antitumor immune response. In support of this hypothesis, we observed that tumor cells expressing Ad5 E1A are over 1,000-fold less tumorigenic than tumor cells that express HPV16 E7 or both HPV16 E7 and E6 in a syngeneic tumor model (61). The decreased tumorigenicity of tumor cells expressing E1A was dependent on a vigorous innate and adaptive immune response directed against tumor cells that express E1A. We have identified several factors that are likely to contribute to the increased immunogenicity of E1A-expressing tumor cells compared to that of E7-expressing tumor cells. E1A, but not E7, sensitizes cells to lysis by NK cells, macrophages, and the killing mechanisms utilized by these effector cells (e.g., tumor necrosis factor alpha [TNF-], TRAIL, Fas, nitric oxide [NO], and perforin-granzyme [8, 9, 16, 39, 48, 64]). Furthermore, the sensitivity of E1A- and E7-expressing murine and human tumor cells to killing by NK cells and macrophages in vitro inversely correlates with their tumorigenicity in vivo (8, 10, 48, 60, 63, 64, 67, 78).
Based on these studies, we hypothesized that, despite many shared biological functions, molecular differences exist between the oncoproteins derived from Ad and HPV that influence the immunogenicities of Ad- compared to HPV-transformed cells. As an initial approach to this issue, we performed genetic mapping studies to determine the regions of E1A necessary to sensitize cells to lysis by NK cells and macrophages. These mapping studies demonstrated that expression of an intact CR1 region of E1A, which encompasses the p300-binding domain, was required to sensitize cells to killing by NK cells and macrophages (47). (For the purposes of this paper, we do not distinguish between p300 and the highly homologous transcriptional coactivator CBP.) The E7 oncoprotein interacts with p300. However, it lacks an N-terminal p300-binding site homologous to that of E1A (2). Studies utilizing a chimeric E1A/E7 gene that included the N terminus and CR1 (p300-binding) domain of E1A fused to CR2 and the C-terminal sequences of E7 demonstrated that the E7-p300-binding site was not equivalent to the E1A-p300-binding site in terms of sensitizing cells to lysis by either NK cells or activated macrophages (47).
The HPV16 E6 oncoprotein also interacts with p300. E1A and E6 have been reported elsewhere to interact spatially in the same functional domains of p300, and both inhibit the coactivator function of p300 (1, 21, 55). Furthermore, E6 can complement a mutant of E1A unable to bind p300 in cellular transformation assays (3). These data suggest that the biological effects of E1A and E6 on p300 function may be similar. Therefore, we determined if, like that of E1A, the expression of HPV16 E6 would sensitize cells to lysis by macrophages and NK cells. These studies indicated that E6 expression sensitized cells to lysis by macrophages but not NK cells. The macrophage-induced killing of cells expressing E6 was independent of p53 function. E1A, but not E6, sensitized cells to lysis by NO and TNF- and to inhibited TNF--induced activation of NF-B.
MATERIALS AND METHODS
Cell lines. H4, a human fibrosarcoma cell line derived from HT1080, and H4-E1A (also known as P2AHT2A) were provided by S. Frisch (La Jolla Cancer Research Institute, La Jolla, Calif.). H4-E1A is an Ad5 E1A-transfected H4 cell line (27). H4-E1A-Rb and H4-E1A-p300 are H4 lines expressing mutant forms of E1A that fail to bind pRb and p300, respectively (48). C33A is an HPV-negative cervical cancer line. C33A and an HPV16 E6-expressing C33A line were provided by J. Huibregtse (Rutgers University, Piscataway, N.J.) (37). MCA-102 is a B6-derived, methylcholanthrene-induced sarcoma cell line and was provided by Nicholas Restifo (49) (National Institutes of Health, Bethesda, Md.). MCA-102-E1A and MCA-102-E7/E6 are MCA-102 cell lines that stably express high levels of Ad5 E1A and HPV16 E7-E6, respectively (64).
C33A, H4, and MCA-102 cell lines expressing HPV16 E6 or Ad5 E1A were derived from clones selected in G418 (Sigma-Aldrich, St. Louis, Mo.) following transfection with pLSXN16E6 or pE1A-neo, by using the Superfect transfection reagent (Qiagen, Valencia, Calif.). G418-resistant colonies were expanded and screened for the expression of Ad5 E1A or HPV16 E6 by Western (47) or Northern (62) analysis, respectively (data not shown). pLSXN16E6 was provided by Denise Galloway (Fred Hutchinson Cancer Research Center, Seattle, Wash.) (32). pE1A-neo was provided by Elizabeth Moran (Temple University, Philadelphia, Pa.) (65). All cell lines were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with antibiotics, 15 mM glucose, and 5% fetal calf serum. Cell lines were periodically tested for contamination with mycoplasma by the Mycotec assay (Bethesda Research Labs, Bethesda, Md.) and were negative.
Macrophage cytolysis assays. Macrophage cytolysis assays were performed as previously described (48). Briefly, bone marrow-derived macrophages extracted from femurs and tibias of C57BL/6 mice were grown in RPMI 1640 medium containing 10% serum and 20% granulocyte-macrophage colony-stimulating factor for approximately 7 days prior to assay. Macrophages were activated in lipopolysaccharide (LPS; 1 μg/ml; Sigma-Aldrich) and gamma interferon (IFN-; 100 U/ml; R&D Systems, Minneapolis, Minn.) for 24 h prior to assay. Target cells were labeled with [3H]thymidine, and standard 48-h cytolysis assays were performed as described elsewhere, with the use of an optimal effector/target ratio of 50:1 (14, 48). The results shown represent the means ± standard errors of the means (SEM) of at least four separate experiments.
NK cell, TNF-, and NO cytolysis assays. Human NK cells were isolated by negative selection with RosetteSep per the manufacturer's instructions (Stem Cell Technologies, Vancouver, British Columbia, Canada). The negatively selected cells were >90% positive for both CD16 and CD56 by fluorescence-activated cell sorting. Target cells were labeled with 51Cr and incubated with NK cells as previously described (63). DETA-NONOate [2,2'-(hydroxynitrosohydrazino)bis-ethaneamine] was used as the NO donor in the NO-dependent cytolysis assays (Calbiochem, La Jolla, Calif.) (76). Cytolysis assays for NO and TNF- were performed as previously described (15, 48). The results shown represent the means ± SEM of at least four separate experiments. The mean percent spontaneous release from all of the target cell lines was less than 20%.
NF-B-dependent transcription. Six-well dishes (2 x 106 cells/plate) of the parental H4 or E1A-, E6-, or E6- and E7-expressing cell lines were seeded 24 h prior to transfection. Cells were then transiently transfected with 0.5 μg of a B-luciferase (B-luc) reporter gene construct/well in 1 ml of serum-free DMEM/well by using Lipofectamine reagent per the manufacturer's instructions (Invitrogen, Carlsbad, Calif.). The B-luc construct contains three consensus NF-B DNA binding sites from the mouse major histocompatibility complex class I (H-2 Kb) promoter (45). In addition, cells were transfected with 0.3 μg of herpes simplex virus thymidine kinase promoter-driven Renilla luciferase (pRL-TK) to control for transfection efficiency. After a 5-h incubation, cells were fed with 1 ml of DMEM-10% fetal bovine serum. Cells were incubated overnight at 37°C. Eighteen hours later cells were stimulated with 20 ng of TNF- (R&D Systems)/ml for 6 h. Cells were subsequently washed with ice-cold phosphate-buffered saline and lysed in 200 μl of 1x Passive Lysis buffer (Promega, Madison, Wis.). Luciferase activity was assessed using the Dual Luciferase Reporter assay system (Promega). Luciferase activity was normalized to Renilla luciferase activity.
Measurement of NO. The production of NO was measured by assaying culture supernatants for the levels of nitrite, which is a stable product of NO. Bone marrow-derived macrophages were activated with LPS and IFN- and cocultivated with H4, H4-E1A, H4-E6, and H4-E7-E6 cells for 48 h as described for the cytolysis assays (47). Nitrite in culture supernatants was measured by the Griess reaction as previously described (23).
Statistics. Data are presented as means ± SEM. The Kruskal-Wallis test was used to compare percent target cell killing among different cell lines and conditions. For pairwise comparisons, the Dunn procedure was used. Analysis of variance via a mixed effects model was also utilized with assays as random effects. Bonferroni adjustment was used to correct for multiple comparisons when appropriate. All the data analyses were carried out using SAS software (SAS Institute Inc., Cary, N.C.). A two-tailed P value of <0.05 was considered statistically significant.
RESULTS
HPV16 E6 expression sensitizes tumor cells to lysis by activated macrophages but not NK cells. In order to determine whether HPV16 E6 expression could sensitize cells to lysis by NK cells and macrophages, human (C33A and H4) or murine (MCA-102) cell lines were established that stably expressed the HPV16 E6 oncogene (Materials and Methods). The MCA-102 cell lines were chosen for this study because prior studies had characterized the parental, E1A-, E7-, and E6-expressing lines in terms of their tumorigenicity in a syngeneic murine tumor model system (64). The H4 lines were selected because we had previously established H4 lines expressing mutant forms of E1A and characterized their sensitivity to lysis by NK cells and macrophages (47). C33A cells were examined to allow a comparison of the ability of E1A or E6 oncogenes to sensitize cells in a cell type that is naturally transformed by HPV.
We first determined whether the expression of Ad5 E1A, HPV16 E6, or HPV16 E7 and E6 (E7-E6) was able to sensitize H4, C33A, or MCA-102 cells to lysis by activated macrophages. As shown in Fig. 1, the expression of E1A and E6 sensitized H4, C33A, and MCA-102 cells to killing by activated macrophages. The expression of HPV16 E7 does not sensitize cells to lysis by activated macrophages (48), nor did E7 inhibit the capacity of E6 to sensitize cells to lysis by macrophages (Fig. 1).
Next, we compared the ability of E6 and E1A to sensitize H4 or C33A cells to lysis by NK cells. E6 expression alone (Fig. 2A) or in combination with E7 (Fig. 2B) failed to sensitize cells to NK cell lysis. The finding that E7 and E6 expression failed to sensitize C33A cells to NK cell lysis is consistent with our previous observation on E7-E6-expressing MCA-102 cells (64). In summary, these data showed that the expression of HPV16 E6 sensitized cells to lysis by macrophages but not NK cells.
Macrophages kill cells expressing E1A or E6 by TNF-- and NO-dependent mechanisms. TNF- and NO are the principal effector mechanisms utilized by activated macrophages to kill tumor cells (9, 35, 38). The lysis of E1A-expressing cells by activated macrophages is dependent on the production of TNF- and NO (9, 48). Therefore, we determined if macrophages kill E6-expressing cells via TNF-, NO, or both TNF-- and NO-dependent mechanisms. The role of TNF- in macrophage-induced killing was examined through the use of macrophages derived from TNF-–/– mice. Inducible NO synthase, also known as NOS2, is utilized by macrophages to generate NO. Therefore, the role of NO in macrophage killing was assessed by incubating macrophages with L-NAME (NG-monomethyl-L-arginine monoacetate), which inhibits the enzymatic activity of inducible NO synthase.
In comparison to macrophages from normal mice, macrophages unable to produce TNF- (Fig. 3A) or NO (Fig. 3B) were impaired in their capacity to kill C33A cells expressing E1A, E6, or E7-E6. To ascertain the relative contributions of TNF and NO in the lysis of H4 cells expressing E1A-, E6-, or E7-E6, macrophage cytolysis assays were simultaneously performed using normal macrophages or macrophages lacking TNF- or NO (Fig. 4). These data demonstrated that both NO and TNF- contributed to the lysis of cells expressing E1A, E6, or E6 and E7 by macrophages. Macrophages lacking either TNF- or NO exhibited an approximately 40% reduction in their capacity to kill E6-expressing cells.
It is possible that the increased NO-dependent killing by macrophages of H4-E6 cells, compared to H4 cells, is due to the ability of E6 to sensitize cells to NO-induced death. Alternatively, in comparison to H4 cells, incubation of H4-E6 cells with macrophages may induce the production of higher levels of NO. In the latter case, the induction of higher levels of NO by E6-expressing cells may result in cell death without altering the intrinsic sensitivity of the cell to NO-induced killing. To address this question, NO was measured from the supernatants of cytolysis assays by using macrophages derived from normal mice or TNF-–/– mice. The production of NO was measured by assaying culture supernatants for the levels of nitrite, which is a stable product of NO. There was no difference in the ability of H4, H4-E1A, H4-E7, or H4-E7-E6-expressing cells to induce the production of NO by macrophages (Fig. 5). Consistent with studies from our laboratory and others, macrophages derived from TNF-–/– mice produced less NO than did macrophages derived from normal mice (44, 48; data not shown). Thus, the decreased ability of macrophages derived from TNF-–/– mice may reflect a deficiency in NO production. In summary, these data suggested that the production of TNF- and NO by macrophages was necessary for the optimal lysis of cells expressing E6.
E1A and E6 differ in their capacities to directly sensitize cells to lysis by rTNF- and NO. We next tested whether the expression of E6, like E1A, would directly sensitize cells to killing by soluble NO or recombinant TNF- (rTNF-). H4 cells expressing E1A, E6, or E7-E6 were incubated with rTNF-, DETA-NONOate (an NO donor), or both rTNF- and DETA-NONOate. In agreement with prior studies (9, 18, 48), H4 cells expressing E1A were more sensitive to lysis by TNF- (Fig. 6A) and NO (48) than parental H4 cells were (Fig. 6B). Furthermore, the combination of TNF and NO was more effective than either substance alone in killing H4-E1A cells (Fig. 6C). In contrast to E1A, E6 expression was unable to sensitize H4 cells to lysis by rTNF- and induced a slight increase in sensitivity to lysis by NO. These data are consistent with prior studies suggesting that E6 expression fails to sensitize cells to lysis by rTNF- (19, 26). Compared to H4-E6 cells, H4-E7-E6 cells appeared to be less sensitive to NO-induced killing. However, this difference in sensitivity was extremely small and not consistent at all concentrations of NO. Consequently, we are uncertain of the biological relevance of this finding. In summary, E1A and E6 both sensitized cells to lysis by macrophages by TNF-- and NO-dependent mechanisms. However, unlike cells expressing E1A, cells expressing E6 were relatively resistant to lysis by the direct effects of TNF-, NO, or both TNF- and NO.
E1A, but not E1A-Rb, E1A-p300, or E6 blocks the TNF-induced activation of the NF-B pathway. Several studies have shown that E1A blocks TNF--induced, transcriptional activation of NF-B (15, 33, 70, 71). This activity of E1A is responsible for sensitizing cells that express E1A to lysis by TNF- (15, 56, 70). We previously showed that the capacity of E1A to sensitize H4 cells to TNF--dependent killing by activated macrophages correlated with the ability of E1A to bind p300-CBP, but not pRb (48). Therefore, we compared the capacities of E1A, E1A-Rb, E1A-p300, and E6 to block the TNF--induced activation of NF-B in H4 cells. These studies demonstrated that E1A and E1A-Rb, but not E1A-p300, E6, or E7-E6 blocked TNF--induced NF-B-dependent transcription (Fig. 7). In contrast to TNF-, incubation of H4 cells with the NO donor DETA-NONOate failed to activate NF-B-dependent transcription (data not shown). In summary, TNF--induced NF-B-dependent transcription was blocked by E1A, but not E6. The ability of E1A to block TNF--induced NF-B-dependent activation and to sensitize cells to TNF--induced lysis correlated with the ability of E1A to bind p300, not pRb.
DISCUSSION
Results from this study demonstrated that the expression of the HPV16 E6 oncoprotein sensitized human (C33A and H4) and murine (MCA-102) tumor cells to lysis by activated macrophages but not NK cells. H4 cells, a clone of HT1080 cells, express a mutant form of p53 (17) and are resistant to lysis by macrophages (Fig. 1) (27, 48). Therefore, the ability of E6 to decrease p53 levels (79) or inhibit p53 function (81) does not contribute to the ability of E6 to sensitize cells to lysis by macrophages. Similarly, the capacity of E1A to sensitize cells to lysis by macrophages is independent of p53 function (12, 13). Macrophages killed tumor cells expressing E6 and E1A, using both TNF-- and NO-dependent mechanisms. However, in contrast to E1A, the ability of E6 to sensitize cells to lysis by soluble rTNF- or DETA-NONOate, a compound that releases NO upon exposure to H2O, was small and inconsistent. Perforin is the predominant killing mechanism utilized by NK cells and cytotoxic T lymphocytes (CTL) (36). Cook et al. demonstrated that expression of E1A sensitized cells to degranulation-dependent (perforin-granzyme) lysis mediated by cytolytic lymphocytes (11). Therefore, the failure of NK cells to selectively kill cells expressing E6 suggests that E6 does not sensitize cells to perforin-granzyme-dependent killing. In total these data suggest that, compared to E1A, the expression of E6 has a more restricted capacity to sensitize cells to lysis by the killing mechanisms utilized by NK cells and macrophages.
The inability of E6 to sensitize cells to lysis by soluble NO and TNF- was unexpected in light of the finding that macrophages utilized these mechanisms to kill cells that express HPV16 E6. The production of NO in macrophages is impaired in macrophages derived from TNF-–/– mice. Accordingly, the impaired ability of TNF-–/– macrophages may be due to impaired generation of NO and NO-dependent killing. However, the molecular basis for the difference in the ability of E1A, compared to E6, to sensitize cells to soluble NO is unclear. These observations also suggest that macrophages utilize effector mechanisms to kill tumor cells that may not be replicated in cytolysis assays with the use of the simple addition of soluble or recombinant forms of the effector molecules.
The molecular mechanisms that enable NK cells and macrophages to selectively kill cells that express E1A are incompletely understood. Prior studies demonstrated that E1A blocks the TNF--induced activation of the antiapoptotic, NF-B pathway. This activity of E1A appears to be responsible for its capacity to sensitize cells to lysis by TNF-. There are conflicting reports on the ability of E6 to sensitize cells to lysis by rTNF (19, 25, 26, 28, 42, 43, 59, 72, 75) or to inhibit TNF--induced activation of the NF-B pathway (26, 55, 72, 75). We found that the expression of E1A, but not E6, sensitized cells to rTNF- and blocked the TNF--induced activation of NF-B. Using H4 cells expressing mutants of E1A that failed to bind pRb or p300, we showed that the capacity of E1A to block the TNF--induced activation of NF-B correlated with the ability of E1A to interact with p300 but not pRb. Prior observations from our laboratory with the same H4 cell lines expressing E1A-p300 or E1A-Rb indicated that the TNF--dependent killing by activated macrophages also correlated with the capacity of E1A to interact with p300. Thus, the abilities of E1A to sensitize H4 tumor cells to lysis by TNF- and to block TNF--induced activation of NF-B both correlated with E1A-p300 binding.
The molecular basis for the E1A-induced inhibition of NF-B is also not clearly delineated. p300 and CBP are transcriptional coadaptor molecules that are essential for the optimal transcriptional activity of NF-B, an activity inhibited by E1A. One mechanism for the ability of E1A to block the TNF--induced activation of the NF-B pathway is via inhibition of the coactivator function of p300-CBP by E1A (57). E1A has also been reported to impair the degradation of IB, thereby blocking translocation of NF-B to the nucleus (70). Alternatively, Cook et al. demonstrated that degradation of IB was not impaired by E1A and that the E1A blocked the transcriptional activity of NF-B by a mechanism that correlated with E1A-pRb binding (15). These results illustrate the complexity of the biological effects of E1A on NF-B activity.
The functional consequences of the interaction of p300 with viral proteins are similarly complex. p300 is a member of a family of transcriptional coadaptor molecules with several distinct functional domains (29). E1A, E7, and E6 interact with p300 in overlapping and unique regions (2, 21, 55). The spatial interaction of these viral oncoproteins with p300 partially explains their common and distinct biological effects on p300 function. For example, E7 interacts predominantly with the C/H1 domain of p300, while E1A interacts primarily with the C/H3 (TRAM) domain. The ability of E7 to interact with p300 appears to result in activities that are shared with E1A such as regulation of E2 transcriptional activity (2). In contrast, the p300-binding domains of E7 and E1A are not equivalent in their capacities to sensitize cells to lysis by NK cells and macrophages (47).
There are additional complexities apart from the spatial interactions of viral oncoproteins with p300 that influence the biological effects on p300 function. For example, although both E1A and simian virus 40 large T antigen interact with p300 in overlapping locations, large T antigen inhibits, whereas E1A enhances, the phosphorylation of p300 (22). E1A and E6 also appear to interact in the same or similar regions of p300. Our data suggested that the interaction of E1A and E6 with p300 resulted in common (induction of sensitivity to lysis by macrophages) and unique (e.g., induction of sensitivity to NK cell killing and inhibition of TNF-induced activation of NF-B) biological effects. The ability of E1A to sensitize cells to lysis by NK cells requires expression of both the p300 binding site of E1A and a portion of exon 2 (40, 47). The expression of exon 2 of E1A can modulate cellular and viral gene expression in and of itself (54). Furthermore, amino acids encoded by exon 2 interact with proteins (e.g., CtBp) that suppress E1A-induced oncogenic transformation (6). Therefore, we hypothesize that the failure of E6 to sensitize cells to NK lysis, despite interacting with p300, is because E6 lacks a functional equivalent to exon 2 of E1A.
The ability of E1A, but not E6, to sensitize cells to NK cell lysis may have important consequences for the oncogenicity of cells that express E1A or E6. Prior studies from our laboratory with the same E1A- and E7-E6-expressing MCA-102 cell lines demonstrated that MCA-102-E1A cells were over 1,000-fold less tumorigenic than MCA-102-E7-E6 cells in syngeneic mice. These differences in tumorigenicity were due to a more effective NK cell and T-cell antitumor response directed against MCA-102 cells that express E1A (7, 41). The difference in the abilities of Ad5 E1A and HPV16 E6 to sensitize cells to lysis by NK cells but not macrophages and the potential biological consequences of this effect are reminiscent of the findings with rodent cells transformed by Ad2, Ad5, or Ad12 (7, 41). Ad12-transformed cells are oncogenic in immunocompetent rodents and are sensitive to lysis by macrophages, but not NK cells. In contrast, Ad2- or Ad5-transformed cells are oncogenic only in rodents that are depleted of NK cells or T cells and are sensitive to lysis by both NK cells and macrophages.
These studies do not exclude an important role for macrophages in the rejection of both Ad- and HPV-transformed cells. Studies of bacterial infections indicate that NK cells are necessary to activate macrophages to attain optimal bactericidal activity (69). Similarly, NK cells may interact with and prime macrophages to mediate tumor clearance. In support of this hypothesis, there is a large literature that implicates macrophages as important effectors in the rejection of cells transformed by small DNA tumor viruses (reference 41 and references therein). Furthermore, we have found that macrophages comprise a large component of the inflammatory infiltrate following the injection of MCA-102-E1A tumor cells in B6 mice (unreported observations).
There are undoubtedly other factors apart from innate immune responses that contribute to the dissimilar oncogenicities of HPV and Ad in humans. HPV-specific cytotoxic T cells in women with HPV-induced carcinomas are ineffective in mediating the clearance of E7-E6-expressing tumor cells, even when such CTL are present in significant numbers (24, 74). Studies utilizing mice transgenic for HPV16 E7 and E6 indicate that E7-specific CTL either ignore or become tolerant to keratinocytes that persistently express E7, thereby rendering these CTL ineffective in mediating antitumor immunity (46, 73). In addition, the urogenital location of HPV-induced malignancies and differences in the replicative cycle and the unique cell tropism of HPV may all contribute to the dissimilar oncogenicities of HPV and Ad.
In summary, the expression of HPV16 E6 sensitized cells to lysis by macrophages, but not NK cells. Macrophages kill E6-expressing cells by both TNF-- and NO-dependent mechanisms. Prior studies indicate that the ability of E1A to sensitize cells to lysis by NK cells and macrophages correlates with the interaction of E1A and p300-CBP. E6 also interacts with and inhibits the function of p300-CBP. In total, these data suggest that the functional consequences of the interaction of E1A or E6 with p300-CBP are not equivalent and may result in important biological differences.
ACKNOWLEDGMENTS
This work was supported by Public Health Services grant RO1-CA76491 and seed grant support funded by the University of Colorado Cancer Center (to J.M.R.) and Cancer Research Institute Predoctoral Emphasis Pathway in Tumor Immunology (to K.M.).
We thank N. Restifo, D. Galloway, J. Huibregtse, E. Moran, and S. Frisch for reagents; S. Benedict and J. Cook for critical reading of the manuscript; and G. Cheatham for secretarial assistance.
REFERENCES
Arany, Z., W. R. Sellers, D. M. Livingston, and R. Eckner. 1994. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 77:799-800.
Bernat, A., N. Avvakumov, J. S. Mymryk, and L. Banks. 2003. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 22:5927-5937.
Bernat, A., P. Massimi, and L. Banks. 2002. Complementation of a p300/CBP defective-binding mutant of adenovirus E1a by human papillomavirus E6 proteins. J. Gen. Virol. 83:829-833.
Bosch, F. X., M. M. Manos, N. Mu?oz, M. Sherman, A. M. Jansen, J. Peto, M. H. Schiffman, V. Moreno, R. Kurman, and K. V. Shah. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87:796-802.
Brokaw, J. L., C. L. Yee, and K. Münger. 1994. A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein. Virology 205:603-607.
Chinnadurai, G. 2004. Modulation of oncogenic transformation by the human adenovirus E1A C-terminal region. Curr. Top. Microbiol. Immunol. 273:139-161.
Cook, J. L., J. B. Hibbs, Jr., and A. M. Lewis, Jr. 1982. DNA virus-transformed hamster cell-host effector cell interactions: level of resistance to cytolysis correlated with tumorigenicity. Int. J. Cancer 30:795-803.
Cook, J. L., C. K. Krantz, and B. A. Routes. 1996. Role of p300-family proteins in E1A oncogene induction of cytolytic susceptibility and tumor cell rejection. Proc. Natl. Acad. Sci. USA 93:13985-13990.
Cook, J. L., D. L. May, B. A. Wilson, B. Holskin, M. J. Chen, D. Shalloway, and T. A. Walker. 1989. Role of tumor necrosis factor-alpha in E1A oncogene-induced susceptibility of neoplastic cells to lysis by natural killer cells and activated macrophages. J. Immunol. 142:4527-4534.
Cook, J. L., T. A. Miura, D. N. Ikle, A. M. Lewis, Jr., and J. M. Routes. 2003. E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo. Cancer Res. 63:3435-3443.
Cook, J. L., T. A. Potter, D. Bellgrau, and B. A. Routes. 1996. E1A oncogene expression in target cells induces cytolytic susceptibility at a post-recognition stage in the interaction with killer lymphocytes. Oncogene 12:833-842.
Cook, J. L., B. A. Routes, C. Y. Leu, T. A. Walker, and K. L. Colvin. 1999. E1A oncogene-induced cellular sensitization to immune-mediated apoptosis is independent of p53 and resistant to blockade by E1B 19 kDa protein. Exp. Cell Res. 252:199-210.
Cook, J. L., B. A. Routes, T. A. Walker, K. L. Colvin, and J. M. Routes. 1999. E1A oncogene induction of cellular susceptibility to killing by cytolytic lymphocytes through target cell sensitization to apoptotic injury. Exp. Cell Res. 251:414-423.
Cook, J. L., T. A. Walker, A. M. Lewis, Jr., H. E. Ruley, F. L. Graham, and S. H. Pilder. 1986. Expression of the adenovirus E1A oncogene during cell transformation is sufficient to induce susceptibility to lysis by host inflammatory cells. Proc. Natl. Acad. Sci. USA 83:6965-6969.
Cook, J. L., T. A. Walker, G. S. Worthen, and J. R. Radke. 2002. Role of the E1A Rb-binding domain in repression of the NF-B-dependent defense against tumor necrosis factor-alpha. Proc. Natl. Acad. Sci. USA 99:9966-9971.
Day, D. B., N. A. Zachariades, and L. R. Gooding. 1994. Cytolysis of adenovirus-infected murine fibroblasts by IFN-gamma-primed macrophages is TNF- and contact-dependent. Cell. Immunol. 157:223-238.
de Belle, I., R. P. Huang, Y. Fan, C. Liu, D. Mercola, and E. D. Adamson. 1999. p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis. Oncogene 18:3633-3642.
Duerksen-Hughes, P., W. S. M. Wold, and L. R. Gooding. 1989. Adenovirus E1A renders infected cells sensitive to cytolysis by tumor necrosis factor. J. Immunol. 143:4193-4200.
Duerksen-Hughes, P. J., J. Yang, and S. B. Schwartz. 1999. HPV 16 E6 blocks TNF-mediated apoptosis in mouse fibroblast LM cells. Virology 264:55-65.
Dyson, N., P. Guida, K. Münger, and E. Harlow. 1992. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol. 66:6893-6902.
Eckner, R., M. E. Ewen, D. Newsome, M. Gerdes, J. A. DeCaprio, J. B. Lawrence, and D. M. Livingston. 1994. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 8:869-884.
Eckner, R., J. W. Ludlow, N. L. Lill, E. Oldread, Z. Arany, N. Modjtahedi, J. A. DeCaprio, D. M. Livingston, and J. A. Morgan. 1996. Association of p300 and CBP with simian virus 40 large T antigen. Mol. Cell. Biol. 16:3454-3464.
Erwig, L. P., D. C. Kluth, G. M. Walsh, and A. J. Rees. 1998. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J. Immunol. 161:1983-1988.
Feltkamp, M. C., G. R. Vreugdenhil, M. P. Vierboom, E. Ras, S. H. van der Burg, J. ter Schegget, C. J. Melief, and W. M. Kast. 1995. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol. 25:2638-2642.
Filippova, M., L. Parkhurst, and P. J. Duerksen-Hughes. 2004. The human papillomavirus 16 E6 protein binds to FADD and protects cells from Fas-triggered apoptosis. J. Biol. Chem. 279:25729-25744.
Filippova, M., H. Song, J. L. Connolly, T. S. Dermody, and P. J. Duerksen-Hughes. 2002. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 277:21730-21739.
Frisch, S. M. 1991. Antioncogenic effect of adenovirus E1A in human tumor cells. Proc. Natl. Acad. Sci. USA 88:9077-9081.
Gaiotti, D., J. Chung, M. Iglesias, M. Nees, P. D. Baker, C. H. Evans, and C. D. Woodworth. 2000. Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol. Carcinog. 27:97-109.
Goodman, R. H., and S. Smolik. 2000. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14:1553-1577.
Graham, F. L., J. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-72.
Green, M., W. Wold, J. Mackey, and P. Rigden. 1979. Analysis of human tonsil and cancer DNAs and RNAs for DNA sequences of group C (serotypes 1, 2, 5 and 6) human adenovirus. Proc. Natl. Acad. Sci. USA 76:6606-6610.
Halbert, C., G. Demers, and D. Galloway. 1991. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65:473-478.
Hassa, P. O., C. Buerki, C. Lombardi, R. Imhof, and M. O. Hottiger. 2003. Transcriptional coactivation of NF-B-dependent gene expression by p300 is regulated by PARP-1. J. Biol. Chem. 278:45145-45153.
Helt, A. M., and D. A. Galloway. 2003. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 24:159-169.
Higuchi, M., N. Higashi, H. Taki, and T. Osawa. 1990. Cytolytic mechanisms of activated macrophages. Tumor necrosis factor and L-arginine-dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages. J. Immunol. 144:1425-1431.
K?gi, D., B. Ledermann, K. Bürki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31-37.
Kao, W. H., S. L. Beaudenon, A. L. Talis, J. M. Huibregtse, and P. M. Howley. 2000. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. J. Virol. 74:6408-6417.
Keller, R., R. Keist, A. Wechsler, T. P. Leist, and P. H. van der Meide. 1990. Mechanisms of macrophage-mediated tumor cell killing: a comparative analysis of the roles of reactive nitrogen intermediates and tumor necrosis factor. Int. J. Cancer 46:682-686.
Klefstrom, J., P. E. Kovanen, K. Somersalo, A. O. Hueber, T. Littlewood, G. I. Evan, A. H. Greenberg, E. Saksela, T. Timonen, and K. Alitalo. 1999. c-Myc and E1A induced cellular sensitivity to activated NK cells involves cytotoxic granules as death effectors. Oncogene 18:2181-2188.
Krantz, C. K., B. A. Routes, M. P. Quinlan, and J. L. Cook. 1996. E1A second exon requirements for induction of target cell susceptibility to lysis by natural killer cells: implications for the mechanism of action. Virology 217:23-32.
Lewis, A. M., Jr., and J. L. Cook. 1985. A new role for DNA virus early proteins in viral carcinogenesis. Science 227:15-20.
Liu, Y., Y. Hong, E. J. Androphy, and J. J. Chen. 2000. Rb-independent induction of apoptosis by bovine papillomavirus type 1 E7 in response to tumor necrosis factor alpha. J. Biol. Chem. 275:30894-30900.
Liu, Y., V. Tergaonkar, S. Krishna, and E. J. Androphy. 1999. Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor alpha correlates with increased accumulation of reactive oxygen species. J. Biol. Chem. 274:24819-24827.
MacMicking, J., Q. W. Xie, and C. Nathan. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15:323-350.
Madrid, L. V., M. W. Mayo, J. Y. Reuther, and A. S. Baldwin, Jr. 2001. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-B through utilization of the IB kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 276:18934-18940.
Melero, I., M. C. Singhal, P. McGowan, H. S. Haugen, J. Blake, K. E. Hellstrom, G. Yang, C. H. Clegg, and L. Chen. 1997. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol. 71:3998-4004.
Miura, T. A., H. Li, K. Morris, S. Ryan, K. Hembre, J. L. Cook, and J. M. Routes. 2004. Expression of an E1A/E7 chimeric protein sensitizes tumor cells to killing by activated macrophages but not NK cells. J. Virol. 78:4646-4654.
Miura, T. A., K. Morris, S. Ryan, J. L. Cook, and J. M. Routes. 2003. Adenovirus E1A, not human papillomavirus E7, sensitizes tumor cells to lysis by macrophages through nitric oxide- and TNF-alpha-dependent mechanisms despite up-regulation of 70-kDa heat shock protein. J. Immunol. 170:4119-4126.
Mule, J. J., J. C. Yang, R. L. Afreniere, S. Shu, and S. A. Rosenberg. 1987. Identification of cellular mechanisms operational in vivo during regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J. Immunol. 139:285-294.
Munger, K., J. R. Basile, S. Duensing, A. Eichten, S. L. Gonzalez, M. Grace, and V. L. Zacny. 2001. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20:7888-7898.
Münger, K., W. Phelps, V. Bubb, P. Howley, and R. Schlegel. 1989. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63:4417-4421.
Münger, K., C. Yee, W. Phelps, J. Pietenpol, H. Moses, and P. Howley. 1991. Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol. 65:3943-3948.
Munoz, N., F. X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K. V. Shah, P. J. Snijders, and C. J. Meijer. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
Mymryk, J. S., and S. T. Bayley. 1993. Induction of gene expression by exon 2 of the major E1A proteins of adenovirus type 5. J. Virol. 67:765-775.
Patel, D., S. M. Huang, L. A. Baglia, and D. J. McCance. 1999. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 18:5061-5072.
Perez, D., and E. White. 2003. E1A sensitizes cells to tumor necrosis factor alpha by downregulating c-FLIPS. J. Virol. 77:2651-2662.
Perkins, N. D., L. K. Felzien, J. C. Betts, K. Leung, D. H. Beach, and G. J. Nabel. 1997. Regulation of NF-B by cyclin-dependent kinases associated with the p300 coactivator. Science 275:523-527.
Phelps, W. C., C. L. Yee, K. Münger, and P. M. Howley. 1988. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53:539-547.
Rapp, L., Y. Liu, Y. Hong, E. J. Androphy, and J. J. Chen. 1999. The bovine papillomavirus type 1 E6 oncoprotein sensitizes cells to tumor necrosis factor alpha-induced apoptosis. Oncogene 18:607-615.
Raska, K., Jr., J. Dougherty, and P. H. Gallimore. 1982. Product of adenovirus type 2 early gene block E1 in transformed cells elicits cytolytic response in syngeneic rats. Virology 117:530-535.
Routes, J., S. Ryan, A. Clase, T. Miura, A. Kuhl, T. A. Potter, and J. A. Cook. 2000. Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J. Immunol. 165:4522-4527.
Routes, J. M., H. Li, S. T. Bayley, S. Ryan, and D. J. Klemm. 1996. Inhibition of IFN-stimulated gene expression and IFN induction of cytolytic resistance correlate with E1A-p300 binding. J. Immunol. 156:1055-1061.
Routes, J. M., and S. Ryan. 1995. Oncogenicity of human papillomavirus- or adenovirus-transformed cells correlates with resistance to lysis by natural killer cells. J. Virol. 69:7639-7647.
Routes, J. M., S. Ryan, J. Steinke, and J. L. Cook. 2000. Dissimilar immunogenicities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development. Virology 277:48-57.
Ruley, H. E., J. Moomaw, C. Chang, J. I. Garrels, M. Furth, and B. R. Franza. 1985 Multistep transformation of an established cell line by the adenovirus E1A and T24 Ha-ras-1 genes, p. 257-264. In J. Feramisco, B. Ozanne, and C. Stiles (ed.), Cold Spring Harbor symposia on quantitative biology. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
Sabbatini, P., S. K. Chiou, L. Rao, and E. White. 1995. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol. Cell. Biol. 15:1060-1070.
Sawada, Y., B. Fohring, T. E. Shenk, and K. Raska, Jr. 1985. Tumorigenicity of adenovirus-transformed cells; region E1A of adenovirus 12 confers resistance to natural killer cells. Virology 147:413-421.
Scheffner, M., B. Werness, J. Huibregtse, A. Levine, and P. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
Scott, M. J., J. J. Hoth, S. A. Gardner, J. C. Peyton, and W. G. Cheadle. 2003. Natural killer cell activation primes macrophages to clear bacterial infection. Am. Surg. 69:679-687.
Shao, R., M. C. Hu, B. P. Zhou, S. Y. Lin, P. J. Chiao, R. H. von Lindern, B. Spohn, and M. C. Hung. 1999. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IB kinases and nuclear factor B activities. J. Biol. Chem. 274:21495-21498.
Shao, R., D. Karunagaran, B. P. Zhou, K. Li, S. S. Lo, J. Deng, P. Chiao, and M. C. Hung. 1997. Inhibition of nuclear factor-B activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J. Biol. Chem. 272:32739-32742.
Spitkovsky, D., S. P. Hehner, T. G. Hofmann, A. Moller, and M. L. Schmitz. 2002. The human papillomavirus oncoprotein E7 attenuates NF-B activation by targeting the IB kinase complex. J. Biol. Chem. 277:25576-25582.
Tindle, R. W., K. Herd, T. Doan, G. Bryson, G. R. Leggatt, P. Lambert, I. H. Frazer, and M. Street. 2001. Nonspecific down-regulation of CD8+ T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter. J. Virol. 75:5985-5997.
Todd, R. W., S. Roberts, C. H. Mann, D. M. Luesley, P. H. Gallimore, and J. C. Steele. 2004. Hum. papillomavirus (HPV) type 16-specific CD8+ T cell responses in women with high grade vulvar intraepithelial neoplasia. Int. J. Cancer 108:857-862.
Vikhanskaya, F., C. Falugi, P. Valente, and P. Russo. 2002. Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line. Int. J. Cancer 97:732-739.
Villarete, L. H., and D. G. Remick. 1995. Nitric oxide regulation of IL-8 expression in human endothelial cells. Biochem. Biophys. Res. Commun. 211:671-676.
Vousden, H. K., and P. S. Jat. 1989. Functional similarity between HPV16 E7, SV40 large T and adenovirus E1a proteins. Oncogene 4:153-158.
Walker, T. A., B. A. Wilson, A. M. Lewis, Jr., and J. L. Cook. 1991. E1A oncogene induction of cytolytic susceptibility eliminates sarcoma cell tumorigenicity. Proc. Natl. Acad. Sci. USA 88:6491-6495.
Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79.
Yew, P. J., and A. J. Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (London) 357:82-85.
Zimmermann, H., R. Degenkolbe, H. U. Bernard, and M. J. O'Connor. 1999. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 73:6209-6219.(John M. Routes, Kristin M)
信息仅供参考，不构成任何之建议、推荐或指引。文章版权属于原著作权人，若您认为此文不宜被收录供大家免费阅读，请邮件或电话通知我们，我们收到通知后，会立即将您的作品从本网站删除。Integrated Department of Immunology, National Jewish Medical and Research Center and the University of Colorado Health Sciences Center
Cancer Center
Departments of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, Colorado
ABSTRACT
The expression of adenovirus serotype 2 or 5 (Ad2/5) E1A sensitizes cells to killing by NK cells and activated macrophages, a property that correlates with the ability of E1A to bind the transcriptional coadaptor proteins p300-CBP. The E6 oncoproteins derived from the high-risk human papillomaviruses (HPV) interact with p300 and can complement mutant forms of E1A that cannot interact with p300 to induce cellular immortalization. Therefore, we determined if HPV type 16 (HPV16) E6 could sensitize cells to killing by macrophages and NK cells. HPV16 E6 expression sensitized human (H4 and C33A) and murine (MCA-102) cell lines to lysis by macrophages but not by NK cells. The lysis of cells that expressed E6 by macrophages was p53 independent but dependent on the production of tumor necrosis factor alpha (TNF-) or nitric oxide (NO) by macrophages. Unlike cytolysis assays with macrophages, E6 expression did not significantly sensitize cells to lysis by the direct addition of NO or TNF-. Like E1A, E6 has been reported to sensitize cells to lysis by TNF- by inhibiting the TNF--induced activation of NF-B. We found that E1A, but not E6, blocked the TNF--induced activation of NF-B, an activity that correlated with E1A-p300 binding. In summary, Ad5 E1A and HPV16 E6 sensitized cells to lysis by macrophages. Unlike E1A, E6 did not block the ability of TNF- to activate NF-B or sensitize cells to lysis by NK cells, TNF-, or NO. Thus, there appears to be a spectrum of common and unique biological activities that result as a consequence of the interaction of E6 or E1A with p300-CBP.
INTRODUCTION
Adenoviruses (Ad) and human papillomaviruses (HPV) are common human pathogens that are able to transform human cells. High-risk HPV (e.g., HPV type 16 [HPV16], HPV18, and HPV31) are the etiologic agents for greater than 95% of cervical carcinomas, the second most common cancer in females worldwide (4, 53). In contrast to HPV, Ad do not appear to be oncogenic in humans (31). Ad and HPV transform cells by similar molecular mechanisms. E7 and E1A are the primary immortalizing genes of HPV and Ad, respectively. HPV E6 and Ad E1B increase the efficiency of E7- and E1A-induced immortalization and are required for complete transformation of cells. The E1A and E7 oncoproteins express homologous conserved regions, conserved region 1 (CR1) and conserved region 2 (CR2). The conserved regions of E1A and E7, which are interchangeable for immortalization function, interact with and inhibit cellular growth regulatory proteins (pRb, p107, p130, and cyclin A) (5, 20, 34, 50-52, 58, 77). Through different molecular mechanisms, the Ad E1B-55K (66, 80) and HPV E6 (55, 68) oncoproteins inhibit the function of p53. The inability of Ad to be oncogenic in humans is puzzling because the E1A and E1B oncogenes fully transform human cells (30), and cells transformed by these oncogenes form tumors in immunodeficient mice (10).
We hypothesize that one factor that influences the dissimilar oncogenicities of Ad and HPV is differences in the capacities of Ad- or HPV-transformed cells to elicit an antitumor immune response. In support of this hypothesis, we observed that tumor cells expressing Ad5 E1A are over 1,000-fold less tumorigenic than tumor cells that express HPV16 E7 or both HPV16 E7 and E6 in a syngeneic tumor model (61). The decreased tumorigenicity of tumor cells expressing E1A was dependent on a vigorous innate and adaptive immune response directed against tumor cells that express E1A. We have identified several factors that are likely to contribute to the increased immunogenicity of E1A-expressing tumor cells compared to that of E7-expressing tumor cells. E1A, but not E7, sensitizes cells to lysis by NK cells, macrophages, and the killing mechanisms utilized by these effector cells (e.g., tumor necrosis factor alpha [TNF-], TRAIL, Fas, nitric oxide [NO], and perforin-granzyme [8, 9, 16, 39, 48, 64]). Furthermore, the sensitivity of E1A- and E7-expressing murine and human tumor cells to killing by NK cells and macrophages in vitro inversely correlates with their tumorigenicity in vivo (8, 10, 48, 60, 63, 64, 67, 78).
Based on these studies, we hypothesized that, despite many shared biological functions, molecular differences exist between the oncoproteins derived from Ad and HPV that influence the immunogenicities of Ad- compared to HPV-transformed cells. As an initial approach to this issue, we performed genetic mapping studies to determine the regions of E1A necessary to sensitize cells to lysis by NK cells and macrophages. These mapping studies demonstrated that expression of an intact CR1 region of E1A, which encompasses the p300-binding domain, was required to sensitize cells to killing by NK cells and macrophages (47). (For the purposes of this paper, we do not distinguish between p300 and the highly homologous transcriptional coactivator CBP.) The E7 oncoprotein interacts with p300. However, it lacks an N-terminal p300-binding site homologous to that of E1A (2). Studies utilizing a chimeric E1A/E7 gene that included the N terminus and CR1 (p300-binding) domain of E1A fused to CR2 and the C-terminal sequences of E7 demonstrated that the E7-p300-binding site was not equivalent to the E1A-p300-binding site in terms of sensitizing cells to lysis by either NK cells or activated macrophages (47).
The HPV16 E6 oncoprotein also interacts with p300. E1A and E6 have been reported elsewhere to interact spatially in the same functional domains of p300, and both inhibit the coactivator function of p300 (1, 21, 55). Furthermore, E6 can complement a mutant of E1A unable to bind p300 in cellular transformation assays (3). These data suggest that the biological effects of E1A and E6 on p300 function may be similar. Therefore, we determined if, like that of E1A, the expression of HPV16 E6 would sensitize cells to lysis by macrophages and NK cells. These studies indicated that E6 expression sensitized cells to lysis by macrophages but not NK cells. The macrophage-induced killing of cells expressing E6 was independent of p53 function. E1A, but not E6, sensitized cells to lysis by NO and TNF- and to inhibited TNF--induced activation of NF-B.
MATERIALS AND METHODS
Cell lines. H4, a human fibrosarcoma cell line derived from HT1080, and H4-E1A (also known as P2AHT2A) were provided by S. Frisch (La Jolla Cancer Research Institute, La Jolla, Calif.). H4-E1A is an Ad5 E1A-transfected H4 cell line (27). H4-E1A-Rb and H4-E1A-p300 are H4 lines expressing mutant forms of E1A that fail to bind pRb and p300, respectively (48). C33A is an HPV-negative cervical cancer line. C33A and an HPV16 E6-expressing C33A line were provided by J. Huibregtse (Rutgers University, Piscataway, N.J.) (37). MCA-102 is a B6-derived, methylcholanthrene-induced sarcoma cell line and was provided by Nicholas Restifo (49) (National Institutes of Health, Bethesda, Md.). MCA-102-E1A and MCA-102-E7/E6 are MCA-102 cell lines that stably express high levels of Ad5 E1A and HPV16 E7-E6, respectively (64).
C33A, H4, and MCA-102 cell lines expressing HPV16 E6 or Ad5 E1A were derived from clones selected in G418 (Sigma-Aldrich, St. Louis, Mo.) following transfection with pLSXN16E6 or pE1A-neo, by using the Superfect transfection reagent (Qiagen, Valencia, Calif.). G418-resistant colonies were expanded and screened for the expression of Ad5 E1A or HPV16 E6 by Western (47) or Northern (62) analysis, respectively (data not shown). pLSXN16E6 was provided by Denise Galloway (Fred Hutchinson Cancer Research Center, Seattle, Wash.) (32). pE1A-neo was provided by Elizabeth Moran (Temple University, Philadelphia, Pa.) (65). All cell lines were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with antibiotics, 15 mM glucose, and 5% fetal calf serum. Cell lines were periodically tested for contamination with mycoplasma by the Mycotec assay (Bethesda Research Labs, Bethesda, Md.) and were negative.
Macrophage cytolysis assays. Macrophage cytolysis assays were performed as previously described (48). Briefly, bone marrow-derived macrophages extracted from femurs and tibias of C57BL/6 mice were grown in RPMI 1640 medium containing 10% serum and 20% granulocyte-macrophage colony-stimulating factor for approximately 7 days prior to assay. Macrophages were activated in lipopolysaccharide (LPS; 1 μg/ml; Sigma-Aldrich) and gamma interferon (IFN-; 100 U/ml; R&D Systems, Minneapolis, Minn.) for 24 h prior to assay. Target cells were labeled with [3H]thymidine, and standard 48-h cytolysis assays were performed as described elsewhere, with the use of an optimal effector/target ratio of 50:1 (14, 48). The results shown represent the means ± standard errors of the means (SEM) of at least four separate experiments.
NK cell, TNF-, and NO cytolysis assays. Human NK cells were isolated by negative selection with RosetteSep per the manufacturer's instructions (Stem Cell Technologies, Vancouver, British Columbia, Canada). The negatively selected cells were >90% positive for both CD16 and CD56 by fluorescence-activated cell sorting. Target cells were labeled with 51Cr and incubated with NK cells as previously described (63). DETA-NONOate [2,2'-(hydroxynitrosohydrazino)bis-ethaneamine] was used as the NO donor in the NO-dependent cytolysis assays (Calbiochem, La Jolla, Calif.) (76). Cytolysis assays for NO and TNF- were performed as previously described (15, 48). The results shown represent the means ± SEM of at least four separate experiments. The mean percent spontaneous release from all of the target cell lines was less than 20%.
NF-B-dependent transcription. Six-well dishes (2 x 106 cells/plate) of the parental H4 or E1A-, E6-, or E6- and E7-expressing cell lines were seeded 24 h prior to transfection. Cells were then transiently transfected with 0.5 μg of a B-luciferase (B-luc) reporter gene construct/well in 1 ml of serum-free DMEM/well by using Lipofectamine reagent per the manufacturer's instructions (Invitrogen, Carlsbad, Calif.). The B-luc construct contains three consensus NF-B DNA binding sites from the mouse major histocompatibility complex class I (H-2 Kb) promoter (45). In addition, cells were transfected with 0.3 μg of herpes simplex virus thymidine kinase promoter-driven Renilla luciferase (pRL-TK) to control for transfection efficiency. After a 5-h incubation, cells were fed with 1 ml of DMEM-10% fetal bovine serum. Cells were incubated overnight at 37°C. Eighteen hours later cells were stimulated with 20 ng of TNF- (R&D Systems)/ml for 6 h. Cells were subsequently washed with ice-cold phosphate-buffered saline and lysed in 200 μl of 1x Passive Lysis buffer (Promega, Madison, Wis.). Luciferase activity was assessed using the Dual Luciferase Reporter assay system (Promega). Luciferase activity was normalized to Renilla luciferase activity.
Measurement of NO. The production of NO was measured by assaying culture supernatants for the levels of nitrite, which is a stable product of NO. Bone marrow-derived macrophages were activated with LPS and IFN- and cocultivated with H4, H4-E1A, H4-E6, and H4-E7-E6 cells for 48 h as described for the cytolysis assays (47). Nitrite in culture supernatants was measured by the Griess reaction as previously described (23).
Statistics. Data are presented as means ± SEM. The Kruskal-Wallis test was used to compare percent target cell killing among different cell lines and conditions. For pairwise comparisons, the Dunn procedure was used. Analysis of variance via a mixed effects model was also utilized with assays as random effects. Bonferroni adjustment was used to correct for multiple comparisons when appropriate. All the data analyses were carried out using SAS software (SAS Institute Inc., Cary, N.C.). A two-tailed P value of <0.05 was considered statistically significant.
RESULTS
HPV16 E6 expression sensitizes tumor cells to lysis by activated macrophages but not NK cells. In order to determine whether HPV16 E6 expression could sensitize cells to lysis by NK cells and macrophages, human (C33A and H4) or murine (MCA-102) cell lines were established that stably expressed the HPV16 E6 oncogene (Materials and Methods). The MCA-102 cell lines were chosen for this study because prior studies had characterized the parental, E1A-, E7-, and E6-expressing lines in terms of their tumorigenicity in a syngeneic murine tumor model system (64). The H4 lines were selected because we had previously established H4 lines expressing mutant forms of E1A and characterized their sensitivity to lysis by NK cells and macrophages (47). C33A cells were examined to allow a comparison of the ability of E1A or E6 oncogenes to sensitize cells in a cell type that is naturally transformed by HPV.
We first determined whether the expression of Ad5 E1A, HPV16 E6, or HPV16 E7 and E6 (E7-E6) was able to sensitize H4, C33A, or MCA-102 cells to lysis by activated macrophages. As shown in Fig. 1, the expression of E1A and E6 sensitized H4, C33A, and MCA-102 cells to killing by activated macrophages. The expression of HPV16 E7 does not sensitize cells to lysis by activated macrophages (48), nor did E7 inhibit the capacity of E6 to sensitize cells to lysis by macrophages (Fig. 1).
Next, we compared the ability of E6 and E1A to sensitize H4 or C33A cells to lysis by NK cells. E6 expression alone (Fig. 2A) or in combination with E7 (Fig. 2B) failed to sensitize cells to NK cell lysis. The finding that E7 and E6 expression failed to sensitize C33A cells to NK cell lysis is consistent with our previous observation on E7-E6-expressing MCA-102 cells (64). In summary, these data showed that the expression of HPV16 E6 sensitized cells to lysis by macrophages but not NK cells.
Macrophages kill cells expressing E1A or E6 by TNF-- and NO-dependent mechanisms. TNF- and NO are the principal effector mechanisms utilized by activated macrophages to kill tumor cells (9, 35, 38). The lysis of E1A-expressing cells by activated macrophages is dependent on the production of TNF- and NO (9, 48). Therefore, we determined if macrophages kill E6-expressing cells via TNF-, NO, or both TNF-- and NO-dependent mechanisms. The role of TNF- in macrophage-induced killing was examined through the use of macrophages derived from TNF-–/– mice. Inducible NO synthase, also known as NOS2, is utilized by macrophages to generate NO. Therefore, the role of NO in macrophage killing was assessed by incubating macrophages with L-NAME (NG-monomethyl-L-arginine monoacetate), which inhibits the enzymatic activity of inducible NO synthase.
In comparison to macrophages from normal mice, macrophages unable to produce TNF- (Fig. 3A) or NO (Fig. 3B) were impaired in their capacity to kill C33A cells expressing E1A, E6, or E7-E6. To ascertain the relative contributions of TNF and NO in the lysis of H4 cells expressing E1A-, E6-, or E7-E6, macrophage cytolysis assays were simultaneously performed using normal macrophages or macrophages lacking TNF- or NO (Fig. 4). These data demonstrated that both NO and TNF- contributed to the lysis of cells expressing E1A, E6, or E6 and E7 by macrophages. Macrophages lacking either TNF- or NO exhibited an approximately 40% reduction in their capacity to kill E6-expressing cells.
It is possible that the increased NO-dependent killing by macrophages of H4-E6 cells, compared to H4 cells, is due to the ability of E6 to sensitize cells to NO-induced death. Alternatively, in comparison to H4 cells, incubation of H4-E6 cells with macrophages may induce the production of higher levels of NO. In the latter case, the induction of higher levels of NO by E6-expressing cells may result in cell death without altering the intrinsic sensitivity of the cell to NO-induced killing. To address this question, NO was measured from the supernatants of cytolysis assays by using macrophages derived from normal mice or TNF-–/– mice. The production of NO was measured by assaying culture supernatants for the levels of nitrite, which is a stable product of NO. There was no difference in the ability of H4, H4-E1A, H4-E7, or H4-E7-E6-expressing cells to induce the production of NO by macrophages (Fig. 5). Consistent with studies from our laboratory and others, macrophages derived from TNF-–/– mice produced less NO than did macrophages derived from normal mice (44, 48; data not shown). Thus, the decreased ability of macrophages derived from TNF-–/– mice may reflect a deficiency in NO production. In summary, these data suggested that the production of TNF- and NO by macrophages was necessary for the optimal lysis of cells expressing E6.
E1A and E6 differ in their capacities to directly sensitize cells to lysis by rTNF- and NO. We next tested whether the expression of E6, like E1A, would directly sensitize cells to killing by soluble NO or recombinant TNF- (rTNF-). H4 cells expressing E1A, E6, or E7-E6 were incubated with rTNF-, DETA-NONOate (an NO donor), or both rTNF- and DETA-NONOate. In agreement with prior studies (9, 18, 48), H4 cells expressing E1A were more sensitive to lysis by TNF- (Fig. 6A) and NO (48) than parental H4 cells were (Fig. 6B). Furthermore, the combination of TNF and NO was more effective than either substance alone in killing H4-E1A cells (Fig. 6C). In contrast to E1A, E6 expression was unable to sensitize H4 cells to lysis by rTNF- and induced a slight increase in sensitivity to lysis by NO. These data are consistent with prior studies suggesting that E6 expression fails to sensitize cells to lysis by rTNF- (19, 26). Compared to H4-E6 cells, H4-E7-E6 cells appeared to be less sensitive to NO-induced killing. However, this difference in sensitivity was extremely small and not consistent at all concentrations of NO. Consequently, we are uncertain of the biological relevance of this finding. In summary, E1A and E6 both sensitized cells to lysis by macrophages by TNF-- and NO-dependent mechanisms. However, unlike cells expressing E1A, cells expressing E6 were relatively resistant to lysis by the direct effects of TNF-, NO, or both TNF- and NO.
E1A, but not E1A-Rb, E1A-p300, or E6 blocks the TNF-induced activation of the NF-B pathway. Several studies have shown that E1A blocks TNF--induced, transcriptional activation of NF-B (15, 33, 70, 71). This activity of E1A is responsible for sensitizing cells that express E1A to lysis by TNF- (15, 56, 70). We previously showed that the capacity of E1A to sensitize H4 cells to TNF--dependent killing by activated macrophages correlated with the ability of E1A to bind p300-CBP, but not pRb (48). Therefore, we compared the capacities of E1A, E1A-Rb, E1A-p300, and E6 to block the TNF--induced activation of NF-B in H4 cells. These studies demonstrated that E1A and E1A-Rb, but not E1A-p300, E6, or E7-E6 blocked TNF--induced NF-B-dependent transcription (Fig. 7). In contrast to TNF-, incubation of H4 cells with the NO donor DETA-NONOate failed to activate NF-B-dependent transcription (data not shown). In summary, TNF--induced NF-B-dependent transcription was blocked by E1A, but not E6. The ability of E1A to block TNF--induced NF-B-dependent activation and to sensitize cells to TNF--induced lysis correlated with the ability of E1A to bind p300, not pRb.
DISCUSSION
Results from this study demonstrated that the expression of the HPV16 E6 oncoprotein sensitized human (C33A and H4) and murine (MCA-102) tumor cells to lysis by activated macrophages but not NK cells. H4 cells, a clone of HT1080 cells, express a mutant form of p53 (17) and are resistant to lysis by macrophages (Fig. 1) (27, 48). Therefore, the ability of E6 to decrease p53 levels (79) or inhibit p53 function (81) does not contribute to the ability of E6 to sensitize cells to lysis by macrophages. Similarly, the capacity of E1A to sensitize cells to lysis by macrophages is independent of p53 function (12, 13). Macrophages killed tumor cells expressing E6 and E1A, using both TNF-- and NO-dependent mechanisms. However, in contrast to E1A, the ability of E6 to sensitize cells to lysis by soluble rTNF- or DETA-NONOate, a compound that releases NO upon exposure to H2O, was small and inconsistent. Perforin is the predominant killing mechanism utilized by NK cells and cytotoxic T lymphocytes (CTL) (36). Cook et al. demonstrated that expression of E1A sensitized cells to degranulation-dependent (perforin-granzyme) lysis mediated by cytolytic lymphocytes (11). Therefore, the failure of NK cells to selectively kill cells expressing E6 suggests that E6 does not sensitize cells to perforin-granzyme-dependent killing. In total these data suggest that, compared to E1A, the expression of E6 has a more restricted capacity to sensitize cells to lysis by the killing mechanisms utilized by NK cells and macrophages.
The inability of E6 to sensitize cells to lysis by soluble NO and TNF- was unexpected in light of the finding that macrophages utilized these mechanisms to kill cells that express HPV16 E6. The production of NO in macrophages is impaired in macrophages derived from TNF-–/– mice. Accordingly, the impaired ability of TNF-–/– macrophages may be due to impaired generation of NO and NO-dependent killing. However, the molecular basis for the difference in the ability of E1A, compared to E6, to sensitize cells to soluble NO is unclear. These observations also suggest that macrophages utilize effector mechanisms to kill tumor cells that may not be replicated in cytolysis assays with the use of the simple addition of soluble or recombinant forms of the effector molecules.
The molecular mechanisms that enable NK cells and macrophages to selectively kill cells that express E1A are incompletely understood. Prior studies demonstrated that E1A blocks the TNF--induced activation of the antiapoptotic, NF-B pathway. This activity of E1A appears to be responsible for its capacity to sensitize cells to lysis by TNF-. There are conflicting reports on the ability of E6 to sensitize cells to lysis by rTNF (19, 25, 26, 28, 42, 43, 59, 72, 75) or to inhibit TNF--induced activation of the NF-B pathway (26, 55, 72, 75). We found that the expression of E1A, but not E6, sensitized cells to rTNF- and blocked the TNF--induced activation of NF-B. Using H4 cells expressing mutants of E1A that failed to bind pRb or p300, we showed that the capacity of E1A to block the TNF--induced activation of NF-B correlated with the ability of E1A to interact with p300 but not pRb. Prior observations from our laboratory with the same H4 cell lines expressing E1A-p300 or E1A-Rb indicated that the TNF--dependent killing by activated macrophages also correlated with the capacity of E1A to interact with p300. Thus, the abilities of E1A to sensitize H4 tumor cells to lysis by TNF- and to block TNF--induced activation of NF-B both correlated with E1A-p300 binding.
The molecular basis for the E1A-induced inhibition of NF-B is also not clearly delineated. p300 and CBP are transcriptional coadaptor molecules that are essential for the optimal transcriptional activity of NF-B, an activity inhibited by E1A. One mechanism for the ability of E1A to block the TNF--induced activation of the NF-B pathway is via inhibition of the coactivator function of p300-CBP by E1A (57). E1A has also been reported to impair the degradation of IB, thereby blocking translocation of NF-B to the nucleus (70). Alternatively, Cook et al. demonstrated that degradation of IB was not impaired by E1A and that the E1A blocked the transcriptional activity of NF-B by a mechanism that correlated with E1A-pRb binding (15). These results illustrate the complexity of the biological effects of E1A on NF-B activity.
The functional consequences of the interaction of p300 with viral proteins are similarly complex. p300 is a member of a family of transcriptional coadaptor molecules with several distinct functional domains (29). E1A, E7, and E6 interact with p300 in overlapping and unique regions (2, 21, 55). The spatial interaction of these viral oncoproteins with p300 partially explains their common and distinct biological effects on p300 function. For example, E7 interacts predominantly with the C/H1 domain of p300, while E1A interacts primarily with the C/H3 (TRAM) domain. The ability of E7 to interact with p300 appears to result in activities that are shared with E1A such as regulation of E2 transcriptional activity (2). In contrast, the p300-binding domains of E7 and E1A are not equivalent in their capacities to sensitize cells to lysis by NK cells and macrophages (47).
There are additional complexities apart from the spatial interactions of viral oncoproteins with p300 that influence the biological effects on p300 function. For example, although both E1A and simian virus 40 large T antigen interact with p300 in overlapping locations, large T antigen inhibits, whereas E1A enhances, the phosphorylation of p300 (22). E1A and E6 also appear to interact in the same or similar regions of p300. Our data suggested that the interaction of E1A and E6 with p300 resulted in common (induction of sensitivity to lysis by macrophages) and unique (e.g., induction of sensitivity to NK cell killing and inhibition of TNF-induced activation of NF-B) biological effects. The ability of E1A to sensitize cells to lysis by NK cells requires expression of both the p300 binding site of E1A and a portion of exon 2 (40, 47). The expression of exon 2 of E1A can modulate cellular and viral gene expression in and of itself (54). Furthermore, amino acids encoded by exon 2 interact with proteins (e.g., CtBp) that suppress E1A-induced oncogenic transformation (6). Therefore, we hypothesize that the failure of E6 to sensitize cells to NK lysis, despite interacting with p300, is because E6 lacks a functional equivalent to exon 2 of E1A.
The ability of E1A, but not E6, to sensitize cells to NK cell lysis may have important consequences for the oncogenicity of cells that express E1A or E6. Prior studies from our laboratory with the same E1A- and E7-E6-expressing MCA-102 cell lines demonstrated that MCA-102-E1A cells were over 1,000-fold less tumorigenic than MCA-102-E7-E6 cells in syngeneic mice. These differences in tumorigenicity were due to a more effective NK cell and T-cell antitumor response directed against MCA-102 cells that express E1A (7, 41). The difference in the abilities of Ad5 E1A and HPV16 E6 to sensitize cells to lysis by NK cells but not macrophages and the potential biological consequences of this effect are reminiscent of the findings with rodent cells transformed by Ad2, Ad5, or Ad12 (7, 41). Ad12-transformed cells are oncogenic in immunocompetent rodents and are sensitive to lysis by macrophages, but not NK cells. In contrast, Ad2- or Ad5-transformed cells are oncogenic only in rodents that are depleted of NK cells or T cells and are sensitive to lysis by both NK cells and macrophages.
These studies do not exclude an important role for macrophages in the rejection of both Ad- and HPV-transformed cells. Studies of bacterial infections indicate that NK cells are necessary to activate macrophages to attain optimal bactericidal activity (69). Similarly, NK cells may interact with and prime macrophages to mediate tumor clearance. In support of this hypothesis, there is a large literature that implicates macrophages as important effectors in the rejection of cells transformed by small DNA tumor viruses (reference 41 and references therein). Furthermore, we have found that macrophages comprise a large component of the inflammatory infiltrate following the injection of MCA-102-E1A tumor cells in B6 mice (unreported observations).
There are undoubtedly other factors apart from innate immune responses that contribute to the dissimilar oncogenicities of HPV and Ad in humans. HPV-specific cytotoxic T cells in women with HPV-induced carcinomas are ineffective in mediating the clearance of E7-E6-expressing tumor cells, even when such CTL are present in significant numbers (24, 74). Studies utilizing mice transgenic for HPV16 E7 and E6 indicate that E7-specific CTL either ignore or become tolerant to keratinocytes that persistently express E7, thereby rendering these CTL ineffective in mediating antitumor immunity (46, 73). In addition, the urogenital location of HPV-induced malignancies and differences in the replicative cycle and the unique cell tropism of HPV may all contribute to the dissimilar oncogenicities of HPV and Ad.
In summary, the expression of HPV16 E6 sensitized cells to lysis by macrophages, but not NK cells. Macrophages kill E6-expressing cells by both TNF-- and NO-dependent mechanisms. Prior studies indicate that the ability of E1A to sensitize cells to lysis by NK cells and macrophages correlates with the interaction of E1A and p300-CBP. E6 also interacts with and inhibits the function of p300-CBP. In total, these data suggest that the functional consequences of the interaction of E1A or E6 with p300-CBP are not equivalent and may result in important biological differences.
ACKNOWLEDGMENTS
This work was supported by Public Health Services grant RO1-CA76491 and seed grant support funded by the University of Colorado Cancer Center (to J.M.R.) and Cancer Research Institute Predoctoral Emphasis Pathway in Tumor Immunology (to K.M.).
We thank N. Restifo, D. Galloway, J. Huibregtse, E. Moran, and S. Frisch for reagents; S. Benedict and J. Cook for critical reading of the manuscript; and G. Cheatham for secretarial assistance.
REFERENCES
Arany, Z., W. R. Sellers, D. M. Livingston, and R. Eckner. 1994. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 77:799-800.
Bernat, A., N. Avvakumov, J. S. Mymryk, and L. Banks. 2003. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 22:5927-5937.
Bernat, A., P. Massimi, and L. Banks. 2002. Complementation of a p300/CBP defective-binding mutant of adenovirus E1a by human papillomavirus E6 proteins. J. Gen. Virol. 83:829-833.
Bosch, F. X., M. M. Manos, N. Mu?oz, M. Sherman, A. M. Jansen, J. Peto, M. H. Schiffman, V. Moreno, R. Kurman, and K. V. Shah. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87:796-802.
Brokaw, J. L., C. L. Yee, and K. Münger. 1994. A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein. Virology 205:603-607.
Chinnadurai, G. 2004. Modulation of oncogenic transformation by the human adenovirus E1A C-terminal region. Curr. Top. Microbiol. Immunol. 273:139-161.
Cook, J. L., J. B. Hibbs, Jr., and A. M. Lewis, Jr. 1982. DNA virus-transformed hamster cell-host effector cell interactions: level of resistance to cytolysis correlated with tumorigenicity. Int. J. Cancer 30:795-803.
Cook, J. L., C. K. Krantz, and B. A. Routes. 1996. Role of p300-family proteins in E1A oncogene induction of cytolytic susceptibility and tumor cell rejection. Proc. Natl. Acad. Sci. USA 93:13985-13990.
Cook, J. L., D. L. May, B. A. Wilson, B. Holskin, M. J. Chen, D. Shalloway, and T. A. Walker. 1989. Role of tumor necrosis factor-alpha in E1A oncogene-induced susceptibility of neoplastic cells to lysis by natural killer cells and activated macrophages. J. Immunol. 142:4527-4534.
Cook, J. L., T. A. Miura, D. N. Ikle, A. M. Lewis, Jr., and J. M. Routes. 2003. E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo. Cancer Res. 63:3435-3443.
Cook, J. L., T. A. Potter, D. Bellgrau, and B. A. Routes. 1996. E1A oncogene expression in target cells induces cytolytic susceptibility at a post-recognition stage in the interaction with killer lymphocytes. Oncogene 12:833-842.
Cook, J. L., B. A. Routes, C. Y. Leu, T. A. Walker, and K. L. Colvin. 1999. E1A oncogene-induced cellular sensitization to immune-mediated apoptosis is independent of p53 and resistant to blockade by E1B 19 kDa protein. Exp. Cell Res. 252:199-210.
Cook, J. L., B. A. Routes, T. A. Walker, K. L. Colvin, and J. M. Routes. 1999. E1A oncogene induction of cellular susceptibility to killing by cytolytic lymphocytes through target cell sensitization to apoptotic injury. Exp. Cell Res. 251:414-423.
Cook, J. L., T. A. Walker, A. M. Lewis, Jr., H. E. Ruley, F. L. Graham, and S. H. Pilder. 1986. Expression of the adenovirus E1A oncogene during cell transformation is sufficient to induce susceptibility to lysis by host inflammatory cells. Proc. Natl. Acad. Sci. USA 83:6965-6969.
Cook, J. L., T. A. Walker, G. S. Worthen, and J. R. Radke. 2002. Role of the E1A Rb-binding domain in repression of the NF-B-dependent defense against tumor necrosis factor-alpha. Proc. Natl. Acad. Sci. USA 99:9966-9971.
Day, D. B., N. A. Zachariades, and L. R. Gooding. 1994. Cytolysis of adenovirus-infected murine fibroblasts by IFN-gamma-primed macrophages is TNF- and contact-dependent. Cell. Immunol. 157:223-238.
de Belle, I., R. P. Huang, Y. Fan, C. Liu, D. Mercola, and E. D. Adamson. 1999. p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis. Oncogene 18:3633-3642.
Duerksen-Hughes, P., W. S. M. Wold, and L. R. Gooding. 1989. Adenovirus E1A renders infected cells sensitive to cytolysis by tumor necrosis factor. J. Immunol. 143:4193-4200.
Duerksen-Hughes, P. J., J. Yang, and S. B. Schwartz. 1999. HPV 16 E6 blocks TNF-mediated apoptosis in mouse fibroblast LM cells. Virology 264:55-65.
Dyson, N., P. Guida, K. Münger, and E. Harlow. 1992. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol. 66:6893-6902.
Eckner, R., M. E. Ewen, D. Newsome, M. Gerdes, J. A. DeCaprio, J. B. Lawrence, and D. M. Livingston. 1994. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 8:869-884.
Eckner, R., J. W. Ludlow, N. L. Lill, E. Oldread, Z. Arany, N. Modjtahedi, J. A. DeCaprio, D. M. Livingston, and J. A. Morgan. 1996. Association of p300 and CBP with simian virus 40 large T antigen. Mol. Cell. Biol. 16:3454-3464.
Erwig, L. P., D. C. Kluth, G. M. Walsh, and A. J. Rees. 1998. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J. Immunol. 161:1983-1988.
Feltkamp, M. C., G. R. Vreugdenhil, M. P. Vierboom, E. Ras, S. H. van der Burg, J. ter Schegget, C. J. Melief, and W. M. Kast. 1995. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol. 25:2638-2642.
Filippova, M., L. Parkhurst, and P. J. Duerksen-Hughes. 2004. The human papillomavirus 16 E6 protein binds to FADD and protects cells from Fas-triggered apoptosis. J. Biol. Chem. 279:25729-25744.
Filippova, M., H. Song, J. L. Connolly, T. S. Dermody, and P. J. Duerksen-Hughes. 2002. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 277:21730-21739.
Frisch, S. M. 1991. Antioncogenic effect of adenovirus E1A in human tumor cells. Proc. Natl. Acad. Sci. USA 88:9077-9081.
Gaiotti, D., J. Chung, M. Iglesias, M. Nees, P. D. Baker, C. H. Evans, and C. D. Woodworth. 2000. Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol. Carcinog. 27:97-109.
Goodman, R. H., and S. Smolik. 2000. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14:1553-1577.
Graham, F. L., J. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-72.
Green, M., W. Wold, J. Mackey, and P. Rigden. 1979. Analysis of human tonsil and cancer DNAs and RNAs for DNA sequences of group C (serotypes 1, 2, 5 and 6) human adenovirus. Proc. Natl. Acad. Sci. USA 76:6606-6610.
Halbert, C., G. Demers, and D. Galloway. 1991. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65:473-478.
Hassa, P. O., C. Buerki, C. Lombardi, R. Imhof, and M. O. Hottiger. 2003. Transcriptional coactivation of NF-B-dependent gene expression by p300 is regulated by PARP-1. J. Biol. Chem. 278:45145-45153.
Helt, A. M., and D. A. Galloway. 2003. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 24:159-169.
Higuchi, M., N. Higashi, H. Taki, and T. Osawa. 1990. Cytolytic mechanisms of activated macrophages. Tumor necrosis factor and L-arginine-dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages. J. Immunol. 144:1425-1431.
K?gi, D., B. Ledermann, K. Bürki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31-37.
Kao, W. H., S. L. Beaudenon, A. L. Talis, J. M. Huibregtse, and P. M. Howley. 2000. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. J. Virol. 74:6408-6417.
Keller, R., R. Keist, A. Wechsler, T. P. Leist, and P. H. van der Meide. 1990. Mechanisms of macrophage-mediated tumor cell killing: a comparative analysis of the roles of reactive nitrogen intermediates and tumor necrosis factor. Int. J. Cancer 46:682-686.
Klefstrom, J., P. E. Kovanen, K. Somersalo, A. O. Hueber, T. Littlewood, G. I. Evan, A. H. Greenberg, E. Saksela, T. Timonen, and K. Alitalo. 1999. c-Myc and E1A induced cellular sensitivity to activated NK cells involves cytotoxic granules as death effectors. Oncogene 18:2181-2188.
Krantz, C. K., B. A. Routes, M. P. Quinlan, and J. L. Cook. 1996. E1A second exon requirements for induction of target cell susceptibility to lysis by natural killer cells: implications for the mechanism of action. Virology 217:23-32.
Lewis, A. M., Jr., and J. L. Cook. 1985. A new role for DNA virus early proteins in viral carcinogenesis. Science 227:15-20.
Liu, Y., Y. Hong, E. J. Androphy, and J. J. Chen. 2000. Rb-independent induction of apoptosis by bovine papillomavirus type 1 E7 in response to tumor necrosis factor alpha. J. Biol. Chem. 275:30894-30900.
Liu, Y., V. Tergaonkar, S. Krishna, and E. J. Androphy. 1999. Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor alpha correlates with increased accumulation of reactive oxygen species. J. Biol. Chem. 274:24819-24827.
MacMicking, J., Q. W. Xie, and C. Nathan. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15:323-350.
Madrid, L. V., M. W. Mayo, J. Y. Reuther, and A. S. Baldwin, Jr. 2001. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-B through utilization of the IB kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 276:18934-18940.
Melero, I., M. C. Singhal, P. McGowan, H. S. Haugen, J. Blake, K. E. Hellstrom, G. Yang, C. H. Clegg, and L. Chen. 1997. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol. 71:3998-4004.
Miura, T. A., H. Li, K. Morris, S. Ryan, K. Hembre, J. L. Cook, and J. M. Routes. 2004. Expression of an E1A/E7 chimeric protein sensitizes tumor cells to killing by activated macrophages but not NK cells. J. Virol. 78:4646-4654.
Miura, T. A., K. Morris, S. Ryan, J. L. Cook, and J. M. Routes. 2003. Adenovirus E1A, not human papillomavirus E7, sensitizes tumor cells to lysis by macrophages through nitric oxide- and TNF-alpha-dependent mechanisms despite up-regulation of 70-kDa heat shock protein. J. Immunol. 170:4119-4126.
Mule, J. J., J. C. Yang, R. L. Afreniere, S. Shu, and S. A. Rosenberg. 1987. Identification of cellular mechanisms operational in vivo during regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J. Immunol. 139:285-294.
Munger, K., J. R. Basile, S. Duensing, A. Eichten, S. L. Gonzalez, M. Grace, and V. L. Zacny. 2001. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20:7888-7898.
Münger, K., W. Phelps, V. Bubb, P. Howley, and R. Schlegel. 1989. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63:4417-4421.
Münger, K., C. Yee, W. Phelps, J. Pietenpol, H. Moses, and P. Howley. 1991. Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol. 65:3943-3948.
Munoz, N., F. X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K. V. Shah, P. J. Snijders, and C. J. Meijer. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
Mymryk, J. S., and S. T. Bayley. 1993. Induction of gene expression by exon 2 of the major E1A proteins of adenovirus type 5. J. Virol. 67:765-775.
Patel, D., S. M. Huang, L. A. Baglia, and D. J. McCance. 1999. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 18:5061-5072.
Perez, D., and E. White. 2003. E1A sensitizes cells to tumor necrosis factor alpha by downregulating c-FLIPS. J. Virol. 77:2651-2662.
Perkins, N. D., L. K. Felzien, J. C. Betts, K. Leung, D. H. Beach, and G. J. Nabel. 1997. Regulation of NF-B by cyclin-dependent kinases associated with the p300 coactivator. Science 275:523-527.
Phelps, W. C., C. L. Yee, K. Münger, and P. M. Howley. 1988. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53:539-547.
Rapp, L., Y. Liu, Y. Hong, E. J. Androphy, and J. J. Chen. 1999. The bovine papillomavirus type 1 E6 oncoprotein sensitizes cells to tumor necrosis factor alpha-induced apoptosis. Oncogene 18:607-615.
Raska, K., Jr., J. Dougherty, and P. H. Gallimore. 1982. Product of adenovirus type 2 early gene block E1 in transformed cells elicits cytolytic response in syngeneic rats. Virology 117:530-535.
Routes, J., S. Ryan, A. Clase, T. Miura, A. Kuhl, T. A. Potter, and J. A. Cook. 2000. Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J. Immunol. 165:4522-4527.
Routes, J. M., H. Li, S. T. Bayley, S. Ryan, and D. J. Klemm. 1996. Inhibition of IFN-stimulated gene expression and IFN induction of cytolytic resistance correlate with E1A-p300 binding. J. Immunol. 156:1055-1061.
Routes, J. M., and S. Ryan. 1995. Oncogenicity of human papillomavirus- or adenovirus-transformed cells correlates with resistance to lysis by natural killer cells. J. Virol. 69:7639-7647.
Routes, J. M., S. Ryan, J. Steinke, and J. L. Cook. 2000. Dissimilar immunogenicities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development. Virology 277:48-57.
Ruley, H. E., J. Moomaw, C. Chang, J. I. Garrels, M. Furth, and B. R. Franza. 1985 Multistep transformation of an established cell line by the adenovirus E1A and T24 Ha-ras-1 genes, p. 257-264. In J. Feramisco, B. Ozanne, and C. Stiles (ed.), Cold Spring Harbor symposia on quantitative biology. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
Sabbatini, P., S. K. Chiou, L. Rao, and E. White. 1995. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol. Cell. Biol. 15:1060-1070.
Sawada, Y., B. Fohring, T. E. Shenk, and K. Raska, Jr. 1985. Tumorigenicity of adenovirus-transformed cells; region E1A of adenovirus 12 confers resistance to natural killer cells. Virology 147:413-421.
Scheffner, M., B. Werness, J. Huibregtse, A. Levine, and P. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
Scott, M. J., J. J. Hoth, S. A. Gardner, J. C. Peyton, and W. G. Cheadle. 2003. Natural killer cell activation primes macrophages to clear bacterial infection. Am. Surg. 69:679-687.
Shao, R., M. C. Hu, B. P. Zhou, S. Y. Lin, P. J. Chiao, R. H. von Lindern, B. Spohn, and M. C. Hung. 1999. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IB kinases and nuclear factor B activities. J. Biol. Chem. 274:21495-21498.
Shao, R., D. Karunagaran, B. P. Zhou, K. Li, S. S. Lo, J. Deng, P. Chiao, and M. C. Hung. 1997. Inhibition of nuclear factor-B activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J. Biol. Chem. 272:32739-32742.
Spitkovsky, D., S. P. Hehner, T. G. Hofmann, A. Moller, and M. L. Schmitz. 2002. The human papillomavirus oncoprotein E7 attenuates NF-B activation by targeting the IB kinase complex. J. Biol. Chem. 277:25576-25582.
Tindle, R. W., K. Herd, T. Doan, G. Bryson, G. R. Leggatt, P. Lambert, I. H. Frazer, and M. Street. 2001. Nonspecific down-regulation of CD8+ T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter. J. Virol. 75:5985-5997.
Todd, R. W., S. Roberts, C. H. Mann, D. M. Luesley, P. H. Gallimore, and J. C. Steele. 2004. Hum. papillomavirus (HPV) type 16-specific CD8+ T cell responses in women with high grade vulvar intraepithelial neoplasia. Int. J. Cancer 108:857-862.
Vikhanskaya, F., C. Falugi, P. Valente, and P. Russo. 2002. Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line. Int. J. Cancer 97:732-739.
Villarete, L. H., and D. G. Remick. 1995. Nitric oxide regulation of IL-8 expression in human endothelial cells. Biochem. Biophys. Res. Commun. 211:671-676.
Vousden, H. K., and P. S. Jat. 1989. Functional similarity between HPV16 E7, SV40 large T and adenovirus E1a proteins. Oncogene 4:153-158.
Walker, T. A., B. A. Wilson, A. M. Lewis, Jr., and J. L. Cook. 1991. E1A oncogene induction of cytolytic susceptibility eliminates sarcoma cell tumorigenicity. Proc. Natl. Acad. Sci. USA 88:6491-6495.
Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79.
Yew, P. J., and A. J. Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (London) 357:82-85.
Zimmermann, H., R. Degenkolbe, H. U. Bernard, and M. J. O'Connor. 1999. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 73:6209-6219.(John M. Routes, Kristin M)
|
微信文章
关注百拇
评论几句
搜索更多
推存给朋友
加入收藏
|